drugset / Trial / NCT00681187

Somatuline Autogel Preference and Health Economy Study

NCT00681187

Phase 4 Completed 26 enrolled Ipsen
RandomizedCrossoverOpen-labelTreatment

Summary

The primary aim of this study is to assess which method of lanreotide Autogel administration patients with neuroendocrine tumours prefer - self/partner administrations or healthcare provided administrations. The study will also assess if self/partner administration can be performed without loss of efficacy and with a preserved safety profile. The impact of self/partner administration on resource utilisation and costs will be studied. In addition, we will also assess the healthcare provider's experience of the two administration practices.

Timeline

Start
2008-06
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Lanreotide Other / unclassified 90 mg
Subject Lanreotide Other / unclassified 120 mg

Indications